
    
      A randomized, double-blinded, multicentre phase III study to access the efficacy and safety
      of olaparib in combination with paclitaxel, compared with placebo in combination with
      paclitaxel in Asian patients with advanced gastric cancer (including gastro-oesophageal
      junction) who have progressed following first line therapy.
    
  